Philip A. Routledge

4.1k total citations · 1 hit paper
91 papers, 2.8k citations indexed

About

Philip A. Routledge is a scholar working on Pharmacology, Economics and Econometrics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Philip A. Routledge has authored 91 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pharmacology, 16 papers in Economics and Econometrics and 13 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Philip A. Routledge's work include Pharmaceutical Practices and Patient Outcomes (13 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Poisoning and overdose treatments (10 papers). Philip A. Routledge is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (13 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Poisoning and overdose treatments (10 papers). Philip A. Routledge collaborates with scholars based in United Kingdom, United States and Netherlands. Philip A. Routledge's co-authors include David G. Shand, Ken Woodhouse, M. S. O'Mahony, Patricia Wilkie, Alison Blenkinsopp, Jonathan Hewitt, Ben Carter, Christine Gratus, Robert Grieve and Sue Wilson and has published in prestigious journals such as The Lancet, Annals of Internal Medicine and PLoS ONE.

In The Last Decade

Philip A. Routledge

88 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Managing the challenge of chemically reactive metabolites in drug development

2011 338 citations Philip A. Routledge et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip A. Routledge United Kingdom	26	564	508	465	431	374	91	2.8k
Haleh Bagheri France	31	253 0.4×	619 1.2×	338 0.7×	373 0.9×	479 1.3×	176	3.0k
Staffan Hägg Sweden	37	413 0.7×	723 1.4×	787 1.7×	623 1.4×	387 1.0×	99	3.8k
Hubert G.M. Leufkens Netherlands	23	230 0.4×	879 1.7×	375 0.8×	398 0.9×	400 1.1×	62	3.0k
Andrew Scott United Kingdom	9	451 0.8×	916 1.8×	1.1k 2.3×	687 1.6×	352 0.9×	18	3.2k
Peter A. G. M. De Smet Netherlands	37	948 1.7×	236 0.5×	1.2k 2.6×	503 1.2×	400 1.1×	166	4.7k
B Kevin Park United Kingdom	8	596 1.1×	1.0k 2.0×	1.1k 2.3×	747 1.7×	557 1.5×	8	2.9k
Annie Fourrier‐Réglat France	31	261 0.5×	916 1.8×	650 1.4×	361 0.8×	799 2.1×	125	3.7k
John R. Horn United States	26	339 0.6×	236 0.5×	431 0.9×	378 0.9×	326 0.9×	118	2.8k
J. R. B. J. Brouwers Netherlands	39	464 0.8×	164 0.3×	1.0k 2.2×	527 1.2×	551 1.5×	196	4.5k
Daniel Sitar Canada	35	605 1.1×	134 0.3×	367 0.8×	813 1.9×	833 2.2×	159	4.4k

Countries citing papers authored by Philip A. Routledge

Since Specialization

Citations

This map shows the geographic impact of Philip A. Routledge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip A. Routledge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip A. Routledge more than expected).

Fields of papers citing papers by Philip A. Routledge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip A. Routledge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip A. Routledge. The network helps show where Philip A. Routledge may publish in the future.

Co-authorship network of co-authors of Philip A. Routledge

This figure shows the co-authorship network connecting the top 25 collaborators of Philip A. Routledge. A scholar is included among the top collaborators of Philip A. Routledge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip A. Routledge. Philip A. Routledge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chaplin, Katherine, et al.. (2023). Antidepressant prescribing patterns and adverse events following introduction of a National Prescribing Indicator to monitor dosulepin usage in Wales. British Journal of Clinical Pharmacology. 89(12). 3596–3605. 1 indexed citations

Routledge, Philip A., et al.. (2023). Improving the spontaneous reporting of suspected adverse drug reactions: An overview of systematic reviews. British Journal of Clinical Pharmacology. 89(8). 2377–2385. 6 indexed citations

Copeland, Lauren, et al.. (2021). Public awareness in Wales of the UK Yellow Card scheme for reporting suspected adverse drug reactions. British Journal of Clinical Pharmacology. 87(8). 3344–3348. 6 indexed citations

Cox, Anthony, et al.. (2020). How do pharmacists contribute to global medication safety?. International Journal of Pharmacy Practice. 28(6). 549–551.

Routledge, Philip A., et al.. (2019). Estimated Versus Observed Expenditure Associated with Medicines Recommended by the All Wales Medicines Strategy Group. PharmacoEconomics - Open. 3(3). 343–350. 8 indexed citations

Routledge, Philip A., et al.. (2018). An evaluation of rational prescribing in hospital outpatient practice in Sierra Leone and assessment of affordability of a prescription as an outcome. Pan African Medical Journal. 31. 174–174. 9 indexed citations

Alam, M Fasihul, David Cohen, Frank Dunstan, Dyfrig Hughes, & Philip A. Routledge. (2017). Impact of the phased abolition of co-payments on the utilisation of selected prescription medicines in Wales. Health Economics. 27(1). 236–243. 3 indexed citations

Damery, Sarah, Christine Gratus, Robert Grieve, et al.. (2011). The use of herbal medicines by people with cancer: a cross-sectional survey. British Journal of Cancer. 104(6). 927–933. 83 indexed citations

Gratus, Christine, Sue Wilson, Sheila Greenfield, et al.. (2009). The use of herbal medicines by people with cancer: a qualitative study. BMC Complementary and Alternative Medicine. 9(1). 14–14. 57 indexed citations

10.

Woodley, Frederick W., Derek Stewart, M Fasihul Alam, et al.. (2008). Session 3C — Policy. International Journal of Pharmacy Practice. 16(Supplement_1). A38–A40. 1 indexed citations

11.

Routledge, Philip A.. (2008). The European Herbal Medicines Directive. Drug Safety. 31(5). 416–418. 26 indexed citations

12.

Thomas, Simon H. L., et al.. (2005). A distance‐learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme. British Journal of Clinical Pharmacology. 60(2). 221–223. 39 indexed citations

13.

Routledge, Philip A., M. S. O'Mahony, & Ken Woodhouse. (2003). Adverse drug reactions in elderly patients. British Journal of Clinical Pharmacology. 57(2). 121–126. 341 indexed citations

14.

Routledge, Philip A., Marie Lindquist, & I. Ralph Edwards. (1999). Spontaneous reporting of suspected adverse reactions to antihistamines: a national and international perspective. Clinical & Experimental Allergy. 29(S3). 240–246. 10 indexed citations

15.

Holgate, Stephen T., Martin K. Church, Peter Howarth, et al.. (1999). Summary of the conclusions. Clinical & Experimental Allergy. 29(S3). IV–VI. 6 indexed citations

16.

Routledge, Philip A., et al.. (1998). Case studies in therapeutics: warfarin resistance and inefficacy in a man with recurrent thromboembolism, and anticoagulant‐associated priapism. British Journal of Clinical Pharmacology. 46(4). 343–346. 20 indexed citations

17.

Renowden, Shelley, et al.. (1985). Oral cholestyramine increases elimination of warfarin after overdose.. BMJ. 291(6494). 513–514. 19 indexed citations

18.

Routledge, Philip A.. (1984). Who needs clinical pharmacology?. BMJ. 289(6456). 1451.2–1451. 3 indexed citations

19.

Routledge, Philip A., W. Wayne Stargel, Aaron Barchowsky, Galen S. Wagner, & David G. Shand. (1982). Control of Lidocaine Therapy. Therapeutic Drug Monitoring. 4(3). 265–270. 17 indexed citations

20.

Routledge, Philip A.. (1977). PREDICTING PATIENTS' WARFARIN REQUIREMENTS. The Lancet. 310(8043). 854–855. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact